# David Liguang Chenn

> David Liguang Chenn is a Series A investor at Oceanpine Capital backing Biotechnology. See 9 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Oceanpine Capital](https://shizune.co/investors/profile/oceanpine-capital)
- Total investments: 9
- Last investment: Jun 2023
- Lead investor: 67%
- Last updated: Aug 2026
- Website: https://oceanpine.net/team_detail.jsp?id=13

David Liguang Chenn is a Series A investor at Oceanpine Capital focused on Biotechnology and Biopharma. Dave Chenn is the CEO and managing partner of Oceanpine Capital. Previously in 2005, Mr. Chenn founded China Century Group and its several subsidiary companies, a large multinational company today, in the areas of technology, finance, energy, tourism and healthcare in major regions of China, Southeast Asia and United Sates. Prior to it, Mr. Chennhad worked as a head of Oracle’s Great China Region Government Industry, director of product management/ marketing in Oracle’s Silicon Valley headquarters for five years, as well as at McKinsey and Emerson Electric in Chicago.Mr. Chenn also serves as both a council member and a global advisory board member of Booth Business School of UChicago, China Green Energy Fund Vice Chairman, Beijing Insititute Technology Vice Chairman of the board, Beijing Film Academy Trustee. With his philanthropy contribution of over $30 million and the great success of his entrepreneurship, he has been awarded as “Top Ten Reformer of China’s Growth in 2017”, “Innovation Leader of China’s Economy in 2016”, etc., and has been received by the top leaders of China several times.Mr. Chenn holds an MBA from University of Chicago Booth Business School, and a BS from Beijing Institute of Technology, China.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 4 | 44% |
| Biopharma | 3 | 33% |
| Health Care | 3 | 33% |
| Medical | 2 | 22% |
| Semiconductor | 2 | 22% |

26 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 3 | 33% |
| Series B | 3 | 33% |
| Seed | 2 | 22% |
| Series C | 1 | 11% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| China | 6 | 67% |
| United States | 3 | 33% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Xingchen New Energy | Xingchen New Energy develops new generation of ultra-high-performance all-vanadium flow energy storage system, fully covering electrolyte, stack and core R&D, manufacturing and production of components, energy storage systems and other products, and provide safer comprehensive energy storage solutions. | $13.9M | Seed | Jun 25, 2023 |  |
| OrthoGuard | By exporting abundant doctor resources, efficient management capabilities, innovative market operation models, and strong capital power, Bone Guardian implements hospital custody, technical assistance, investment holdings, and the establishment of demonstration diagnosis and treatment centers in China to build China’s most A new type of medicalgroup with innovation and high reputation. The Bone Guardian Doctor Group positions itself as a comprehensive orthopedic medical service organization integrating diagnosis and treatment services, hospital management, supply chain management, rehabilitation management, and education and training. |  | Series A | Dec 24, 2021 |  |
| Yuchuang Semiconductor | Erised Semiconductor is a circuit designer and manufacturer that provides users with display driver and power management chips. The applications can be found in radiofrequency applications, discrete devices, and other products. | $15.7M | Series A | Dec 21, 2021 |  |
| Juventas | Juventas is a provider and developer of innovative immune cell therapeutic drugs. The company's first investigational new drug application for the cell therapeutic product CNCT19 has been officially accepted by the National Medical Products Administration. Comprehensive product pipelines will be developed and promoted constantly to provideeffective treatment for malignant hematological neoplasms such as leukemia and lymphoma. | $63.3M | Series C | Jul 12, 2021 |  |
| Immune-Onc Therapeutics | Immune-Onc Therapeutics is a newly established bio-pharmaceutical company that focuses on developing innovative therapeutic antibodies for cancer treatment. The company applies the latest scientific insights and expertise in drug development to advance novel immuno-oncology products and bring new treatment options to cancer patients. | $73M | Series B | Mar 30, 2021 |  |
| Moore Threads | Moore Threads is providing Graphics Processing Unit technology and services to corporate clients in a wide variety of sectors such as gaming, the creative industry, and artificial intelligence. The company was founded in 2020 and is based in Beijing, China. |  | Seed | Feb 25, 2021 |  |
| LakeShore Biopharma | Yisheng Biopharma is a global, fully integrated biopharmaceutical company engaged in discovering, developing and commercializing innovative biotherapeutics for cancers and infectious diseases using our novel PIKA® immunomodulating technology. PIKA technology augments both innate and adaptive immune responses through the TLR3, RIG-I and MDA5pathways. Products in clinical development include YS-ON-001 for the treatment of advanced solid tumors, YS-HBV-001 hepatitis B vaccine and the PIKA rabies vaccine for accelerated protection against rabies infection. | $130M | Series B | Feb 24, 2021 |  |
| Teon Therapeutics | Teon Therapeutics is a clinical-stage biopharmaceutical company dedicated to improving the lives of cancer patients by developing a focused portfolio of small molecules that inhibit the immunosuppressive and cancer-promoting signaling pathways in the tumor microenvironment. Teon's lead program is an A2BR-specific antagonist that will enterPhase1b trials in 2021. | $30M | Series A | Feb 23, 2021 |  |
| hireEZ | At hireEZ, our mission is to make outbound recruiting easy. We’re dedicated to helping recruiters proactively bring jobs to people and give organizations the solutions they need to make the switch from inbound to outbound recruiting to achieve their business goals, hire the right people and build more inclusive workplaces. That’s why we developedhireEZ (formerly Hiretual), an AI-powered outbound recruitment platform. With hireEZ, you can execute a strategically scalable approach to build your workforce of the future. | $13M | Series B | Aug 13, 2020 |  |

9 of 9 investments shown.

## Co-investors
- [Shenzhen Capital Group](https://shizune.co/investors/profile/shenzhen-capital-group) — VC Fund, 2 deals together
- [Adjuvant Capital](https://shizune.co/investors/profile/adjuvant-capital) — VC Fund, 1 deal together
- [AIHC Capital](https://shizune.co/investors/profile/aihc-capital) — VC Fund, 1 deal together
- [BOCOM International](https://shizune.co/investors/profile/bocom-international) — VC Fund, 1 deal together
- [ByteDance](https://shizune.co/investors/profile/bytedance) — VC Fund, 1 deal together
- [China Merchants Venture Capital](https://shizune.co/investors/profile/china-merchants-capital) — VC Fund, 1 deal together

## About Oceanpine Capital

VC Fund · Central, Hong Kong

Oceanpine Capital is a professional investment management firm dedicated to long-term investment with a focus on value creation. We provide long-term capital and professional value-added services to high-growth enterprises and start-up companies.Oceanpine Capital is headquartered in Hong Kong with offices in Beijing and San Francisco. We focus oninvestment opportunities in the TMT, consumption upgrade, advanced manufacturing, and healthcare sectors. We mainly invest in private companies with rapid growth, but also look at some opportunities in public companies.Our professional team consists of entrepreneurs, investment professionals, investment bankers and company executives with proven track records. As a team, we stand out in terms of providing strategic resources support and professional value-added services to our investee companies along with our capital.

4 contacts available at Oceanpine Capital.

| Name | Title | Profile |
| --- | --- | --- |
| Adam Sun | Managing Partner | https://shizune.co/investors/profile/adam-sun |
| David Liguang Chenn | Chief executive officer | https://shizune.co/investors/profile/david-chenn-liguang |
| Dongjun Ma | Managing Partner | https://shizune.co/investors/profile/dongjun-ma |
| Shirley Hu | Managing Director | https://shizune.co/investors/profile/shirley-hu |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does David Liguang Chenn invest in?

David Liguang Chenn invests primarily in Biotechnology, Biopharma and Health Care startups, most often at Series A and Series B stage. Most of the 9 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did David Liguang Chenn last invest?

The most recent investment recorded for David Liguang Chenn closed in Jun 2023. Shizune tracks 9 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co